Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics FGFR3 Mutation Assays

Rosetta Genomics said today that it will commercially launch two FGFR3 gene mutation assays next week at the American Urological Association annual meeting.

One assay is intended for diagnostic monitoring using urine samples to detect recurrences of FGFR3-positive low-grade bladder cancers, while the other is intended to be used in conjunction with Ki67 expression to tissue-based prognostication at the initial diagnosis of bladder cancer. The microRNA tests are designed to be used in conjunction the company's FISH technology to help urologists better manage patients through improved prognostication and non-invasive recurrence monitoring, Rosetta said.